Gener8 Maritime, Inc. (GNRT) Forms $5.69 Double Bottom; Last Week CareDx, (CDNA) Coverage

Gener8 Maritime, Inc. (GNRT) formed double bottom with $5.46 target or 4.00% below today’s $5.69 share price. Gener8 Maritime, Inc. (GNRT) has $473.79M valuation. The stock decreased 1.56% or $0.09 during the last trading session, reaching $5.69. About 99,445 shares traded. Gener8 Maritime, Inc. (NYSE:GNRT) has declined 26.90% since February 28, 2017 and is downtrending. It has underperformed by 43.60% the S&P500.

Among 5 analysts covering CareDx (NASDAQ:CDNA), 5 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. CareDx had 10 analyst reports since September 25, 2015 according to SRatingsIntel. Piper Jaffray maintained CareDx, Inc (NASDAQ:CDNA) rating on Monday, January 8. Piper Jaffray has “Buy” rating and $10.0 target. The rating was maintained by Mizuho with “Buy” on Tuesday, June 14. On Sunday, September 24 the stock rating was maintained by Piper Jaffray with “Buy”. As per Monday, October 9, the company rating was maintained by Craig Hallum. The firm has “Market Perform” rating by Raymond James given on Monday, September 28. The stock of CareDx, Inc (NASDAQ:CDNA) has “Outperform” rating given on Wednesday, September 27 by Raymond James. H.C. Wainwright maintained CareDx, Inc (NASDAQ:CDNA) rating on Wednesday, January 31. H.C. Wainwright has “Buy” rating and $12.0 target. The stock of CareDx, Inc (NASDAQ:CDNA) earned “Buy” rating by Craig Hallum on Friday, September 25. See CareDx, Inc (NASDAQ:CDNA) latest ratings:

31/01/2018 Broker: H.C. Wainwright Rating: Buy New Target: $12.0 Maintain
08/01/2018 Broker: Piper Jaffray Rating: Buy New Target: $10.0 Maintain
27/11/2017 Broker: H.C. Wainwright Rating: Buy New Target: $12 Initiates Coverage On
09/10/2017 Broker: Craig Hallum Rating: Buy New Target: $10.0 Maintain
27/09/2017 Broker: Raymond James Old Rating: Market Perform New Rating: Outperform Upgrade
24/09/2017 Broker: Piper Jaffray Rating: Buy New Target: $3.0 Maintain

Analysts await Gener8 Maritime, Inc. (NYSE:GNRT) to report earnings on March, 12. They expect $-0.26 EPS, down 213.04% or $0.49 from last year’s $0.23 per share. After $-0.39 actual EPS reported by Gener8 Maritime, Inc. for the previous quarter, Wall Street now forecasts -33.33% EPS growth.

Among 6 analysts covering Gener8 Maritime (NYSE:GNRT), 2 have Buy rating, 0 Sell and 4 Hold. Therefore 33% are positive. Gener8 Maritime has $17 highest and $6 lowest target. $9’s average target is 58.17% above currents $5.69 stock price. Gener8 Maritime had 15 analyst reports since September 14, 2015 according to SRatingsIntel. The company was maintained on Tuesday, May 30 by Jefferies. The firm has “Buy” rating given on Wednesday, May 4 by Seaport Global. The rating was maintained by Morgan Stanley on Monday, February 12 with “Equal-Weight”. The firm has “Buy” rating given on Monday, July 3 by Jefferies. The stock has “Hold” rating by Citigroup on Tuesday, January 23. The rating was downgraded by Evercore on Tuesday, January 23 to “In-Line”. As per Monday, August 7, the company rating was maintained by Jefferies. Jefferies maintained the shares of GNRT in report on Thursday, October 19 with “Buy” rating. The stock of Gener8 Maritime, Inc. (NYSE:GNRT) earned “Neutral” rating by UBS on Thursday, January 4. The company was maintained on Friday, January 26 by Jefferies.

CareDx, Inc., together with its subsidiaries, focuses on the discovery, development, and commercialization of diagnostic surveillance solutions for transplant patients in North America, Europe, the Middle East, Africa, and Latin America. The company has market cap of $162.61 million. The firm operates through two divisions, CareDx and Olerup. It currently has negative earnings. The Company’s commercialized testing solution includes the AlloMap heart transplant molecular test , a gene expression test that helps clinicians monitor and identify heart transplant recipients with stable graft function who have a low probability of moderate/severe acute cellular rejection.

The stock increased 1.34% or $0.075 during the last trading session, reaching $5.685. About 21,250 shares traded. CareDx, Inc (NASDAQ:CDNA) has declined 74.10% since February 28, 2017 and is downtrending. It has underperformed by 90.80% the S&P500.